Vertex Pharmaceuticals Inc (VRTX)
Nasdaq · Common stock · Pharmaceutical Preparations
As of Oct 21, 2:16 PM ET15 min delayedAbout 15 minutes behind the market. Every member plan is real time.
Follow VRTX in real time
Real-time quotes, Pro Charting, the scanner and the alert feed on VRTX and every other US listing.
Start 5 days freeTry Premium Membership free for 5 days. Card required. After 5 days it is $149 per month or $1,099 per year until you cancel. First-time members only.
VRTX at a glance
Key statistics
$130.44B
Market capitalization
- Previous close
- $514.65
- Open
- $514.22
- Day range
- $511.12 – $521.66
- Volume
- 661.7K
- Average volume (30 sessions)
- 1.14M
- Shares outstanding
- 253.81M
- Price / earnings
- 29.6
- Earnings per share
- $17.38
- Price / book
- 6.4
- Price / sales
- 10.4
- Beta (1 year, vs SPY)
- 0.50
Where the price sits in its year
52-week range
75% of the range
- Below the 52-week high
- -6.9%
- Above the 52-week low
- +29.4%
Completed sessions through Oct 20, 2026
Technical snapshot
Below its 50-day average, above its 200-day
- 20-day average
- $509.71+1.0%
- 50-day average
- $522.47-1.5%
- 200-day average
- $476.46+8.0%
Between the conventional 30 and 70 bands.
+6.1%
1 week
+0.8%
1 month
+8.9%
3 months
+13.5%
Year to date
+23.5%
1 year
Price change over each window, from completed sessions. Past performance does not indicate future results.
Every plan: MACD, ATR, the 20- and 50-day ranges, five-year and all-history extremes and the full indicator set, live on Pro Charting.The member platform, in real time
What members do with VRTX
VRTX on Pro Charting
Every intraday interval in real time, the drawing kit and the full set of technical studies on VRTX.
See the plans →
Every planScreen names like VRTX
The real-time scanner: price, volume, technical, fundamental and chart-pattern filters across the whole US market.
See the plans →
Analysis Tools OnlySet a price line on VRTX
Put VRTX on your watchlist, draw the levels you care about, and My Dashboard tracks where it trades against them.
See the plans →
Stock Alerts + ToolsOpen alerts on VRTX
See whether there is an open premium alert on VRTX, with its entry, stop and exit, each one reviewed by an analyst before it is sent.
See the plans →
From the public news wire
VRTX headlines
- Vertex’s Crinetics Deal Balances Growth with Integration Risk
Investing.com · Jul 8, 2026
SEC Form 4, most recent first
Insider filings
Garber Alan M
+29.272
Director · Grant or award
$15.00K · Oct 15, 2026
SACHS BRUCE I
+92.694
Director · Grant or award
$47.50K · Oct 15, 2026
van Grunsven Jasper
+8.7K
EVP, CP and NPPO · Grant or award
· Sep 8, 2026
Ambrose Kristen
+5.0K
SVP & Chief Accounting Officer · Grant or award
· Aug 28, 2026
SACHS BRUCE I
−6.0K
Director · Gift
· Aug 27, 2026
Sachdev Amit
+8.3K
EVP Chief Patient & Ext Af Off · Grant or award
· Jul 21, 2026
Tatsis Ourania
+8.3K
EVP, Chief Reg. & Quality Off. · Grant or award
· Jul 21, 2026
SACHS BRUCE I
+99.941
Director · Grant or award
$47.50K · Jul 15, 2026
About Vertex Pharmaceuticals Inc
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio, and Alyftrek for cystic fibrosis, where Vertex therapies remain the standard of care globally. Vertex is focused on diversifying its portfolio through Casgevy (gene-editing therapy for beta thalassemia and sickle-cell disease), Journavx (non-opioid pain drug for moderate-to-severe acute pain), and Palsonify (for acromegaly). Additionally, Vertex is evaluating small-molecule inhibitors of APOL1-mediated kidney diseases, cell therapies to deliver a functional cure for type 1 diabetes, povetacicept (for IgA nephropathy).
- Exchange
- Nasdaq
- Security
- Common stock
- Industry
- Pharmaceutical Preparations
- Headquarters
- Boston, MA
- Employees
- 6,400
- Listed since
- Jul 31, 1991
- Website
- vrtx.com
Pick the desk that fits how you trade
Analysis Tools Only for the real-time scanner, Pro Charting and the research desk. Stock Alerts + Tools for the human-reviewed alert feed. Premium Membership for both, at one price.
Try Premium Membership free for 5 days. Card required. After 5 days it is $149 per month or $1,099 per year until you cancel. First-time members only.
Other plans from $39 a month. Pay by card, Apple Pay, Google Pay, Link, Cash App Pay or Amazon Pay through Stripe.